[go: up one dir, main page]

EP1606237A1 - 2-(butyl-1-sulfonylamino)-n- 1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamide, son utilisation comme medicament et preparations pharmaceutiques contenant ce compose - Google Patents

2-(butyl-1-sulfonylamino)-n- 1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamide, son utilisation comme medicament et preparations pharmaceutiques contenant ce compose

Info

Publication number
EP1606237A1
EP1606237A1 EP04717628A EP04717628A EP1606237A1 EP 1606237 A1 EP1606237 A1 EP 1606237A1 EP 04717628 A EP04717628 A EP 04717628A EP 04717628 A EP04717628 A EP 04717628A EP 1606237 A1 EP1606237 A1 EP 1606237A1
Authority
EP
European Patent Office
Prior art keywords
sulfonylamino
butyl
propyl
methoxypyridin
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04717628A
Other languages
German (de)
English (en)
Inventor
Joachim Brendel
Heinz Goegelein
Klaus Wirth
Gert Ulrich Kuerzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of EP1606237A1 publication Critical patent/EP1606237A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Definitions

  • the compound is useful in the treatment of supraventricular arrhythmias, for example, atrial fibrillation or atrial flutter.
  • the compound can be used to terminate existing atrial fibrillation or flutter to regain the sinus rhythm (cardioversion). In addition, it reduces the susceptibility to the emergence of new flicker events (preservation of the sinus rhythm, prophylaxis).
  • the compound of the formula I according to the invention and its physiologically tolerable salts can be used on animals, preferably on mammals, and in particular on humans, as medicaments on their own or in the form of pharmaceutical preparations.
  • the present invention is also the compound of formula I and their physiologically acceptable salts for use as medicaments, their use in the therapy and prophylaxis of

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne le composé 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-méthoxy-pyridin-3-yl)-propyl]-benzamide représenté par la formule (I), ainsi que les sels pharmaceutiquement acceptables de ce composé. L'invention concerne en outre la production et l'utilisation de ce composé ou de ses sels pharmaceutiquement acceptables, notamment en traitement et prévention d'arythmies auriculaires, par exemple de la fibrillation auriculaire (fibrillation atriale) ou du flutter auriculaire (flutter atrial).
EP04717628A 2003-03-18 2004-03-05 2-(butyl-1-sulfonylamino)-n- 1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamide, son utilisation comme medicament et preparations pharmaceutiques contenant ce compose Withdrawn EP1606237A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10312073 2003-03-18
DE10312073A DE10312073A1 (de) 2003-03-18 2003-03-18 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3yl)-propyl]-benzamid, dessen Verwendung als Medikament sowie dieses enthaltende pharmazeutische Zubereitungen
PCT/EP2004/002247 WO2004083157A1 (fr) 2003-03-18 2004-03-05 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamide, son utilisation comme medicament et preparations pharmaceutiques contenant ce compose

Publications (1)

Publication Number Publication Date
EP1606237A1 true EP1606237A1 (fr) 2005-12-21

Family

ID=32920928

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04717628A Withdrawn EP1606237A1 (fr) 2003-03-18 2004-03-05 2-(butyl-1-sulfonylamino)-n- 1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamide, son utilisation comme medicament et preparations pharmaceutiques contenant ce compose

Country Status (21)

Country Link
EP (1) EP1606237A1 (fr)
JP (1) JP2006520343A (fr)
KR (1) KR20050110681A (fr)
CN (1) CN100361943C (fr)
AR (1) AR043622A1 (fr)
AU (1) AU2004222137A1 (fr)
BR (1) BRPI0408441A (fr)
CA (1) CA2519022A1 (fr)
DE (1) DE10312073A1 (fr)
HR (1) HRP20050815A2 (fr)
MA (1) MA27749A1 (fr)
MX (1) MXPA05009763A (fr)
MY (1) MY176510A (fr)
NO (1) NO20054472L (fr)
NZ (1) NZ542476A (fr)
PE (1) PE20050307A1 (fr)
RS (1) RS20050690A (fr)
RU (1) RU2333202C2 (fr)
TW (1) TW200500342A (fr)
WO (1) WO2004083157A1 (fr)
ZA (1) ZA200506328B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
DE102005028845A1 (de) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
EP1909572A4 (fr) * 2005-07-22 2010-09-08 Merck Sharp & Dohme Inhibiteurs des canaux potassiques
JP5685203B2 (ja) * 2009-05-29 2015-03-18 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE167473T1 (de) * 1990-08-20 1998-07-15 Eisai Co Ltd Sulfonamid-derivate
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004083157A1 *

Also Published As

Publication number Publication date
JP2006520343A (ja) 2006-09-07
TW200500342A (en) 2005-01-01
NZ542476A (en) 2008-05-30
NO20054472L (no) 2005-09-27
MY176510A (en) 2020-08-12
AR043622A1 (es) 2005-08-03
WO2004083157A1 (fr) 2004-09-30
HK1086819A1 (en) 2006-09-29
ZA200506328B (en) 2006-04-26
HRP20050815A2 (en) 2006-09-30
RU2005132163A (ru) 2006-04-10
CA2519022A1 (fr) 2004-09-30
PE20050307A1 (es) 2005-06-08
KR20050110681A (ko) 2005-11-23
DE10312073A1 (de) 2004-09-30
MA27749A1 (fr) 2006-02-01
BRPI0408441A (pt) 2006-04-04
AU2004222137A1 (en) 2004-09-30
RS20050690A (sr) 2008-04-04
CN100361943C (zh) 2008-01-16
RU2333202C2 (ru) 2008-09-10
CN1756728A (zh) 2006-04-05
MXPA05009763A (es) 2006-01-27

Similar Documents

Publication Publication Date Title
EP1349846B1 (fr) Amides d'acides furane et thiophene carboxyliques aryles ayant un effet de blocage de canal de potassium
EP1385820B1 (fr) Amides d'acide anthranilique, leur procede de production, leur utilisation en tant qu'antiarythmisants et preparations pharmaceutiques les renfermant
EP1341764B1 (fr) Composes bisaryl azotes a substitution ortho servant d'inhibiteurs de canaux de potassium
EP1339675A1 (fr) Composes bisaryle substitues en ortho et meta, leur procede de fabrication, leur utilisation comme medicaments, et preparations pharmaceutiques les renfermant
WO2002087568A1 (fr) Utilisation d'amides d'acide anthranilique en tant que medicaments servant au traitement d'arythmies et preparations pharmaceutiques les renfermant
DE69837564T2 (de) Azaheterozyklische derivate zur behandlung von haarausfall und neurologischer krankheiten
DE69908421T2 (de) Pharmazeutische zusammensetzung enthaltend eine kombination der dextro- und laevo-isomeren von sotalol
JP3120810B2 (ja) 神経変性疾患を治療するための化合物の製造方法
EP1605976B1 (fr) ASSOCIATION D'AMIDES DE L'ACIDE PHENYLCARBOXYLIQUE ET D'INHIBITEURS DU CANAL IKr ET UTILISATION DE CETTE ASSOCIATION POUR TRAITER DES ARYTHMIES ATRIALES
EP1606237A1 (fr) 2-(butyl-1-sulfonylamino)-n- 1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamide, son utilisation comme medicament et preparations pharmaceutiques contenant ce compose
DE2802864A1 (de) 3-isobutoxy-2-pyrrolidino-n-phenyl- n-benzylpropylamin, verfahren zu seiner herstellung und es enthaltende arzneimittel
DE69919789T2 (de) Loratadin zur Verwendung als Antiarrhythmikum
EP1720549A1 (fr) Kv1.5-bloquant pour l'augmentation selective de la contractilite de l'oreillette et le traitement de l'insuffisance cardiaque
DE1695785C3 (de) 2-Aminomethyl-beitzofurane, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Präparate
DE10341233A1 (de) Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
DE60311134T2 (de) Oromukosale formulierung und herstellungsverfahren dafür
US20080081926A1 (en) Sulfonylaminobenzoic acid and salt
AT358009B (de) Verfahren zur herstellung von neuen 2-(4- hydroxy-3-(alkylthio-, alkylsulfinyl- oder alkylsulfonyl) phenyl)-aethylaminen, deren estern und salzen
DE2802208A1 (de) Antiarrhythmisches chinuclidin carbonsaeure-xylidid sowie verfahren zur herstellung dieser und aehnlicher verbindungen
DE2030693B2 (de) Säureadditionssalze von N-p-Methoxybenzyl-N', N'-dimethylguanidin, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen, welche diese Verbindungen enthalten
HK1086819B (en) 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]- benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051018

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RTI1 Title (correction)

Free format text: 2-(BUTYL-1-SULFONYLAMINO)-N- 1(R)-(6-METHOXY-PYRIDIN-3-YL)-PROPYL -BENZAMID, THE USE THEREOF IN THE FORM OF DRUG AN PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUND

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20091125